All manuscripts
Publications CAR T Cells

TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

Published Journal Nature Communications

Share
14 pages TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial — Nature Communications, 2025

Overview

P-BCMA-ALLO1 is an allogeneic anti-BCMA CAR-T therapy with a TSCM-predominant phenotype. Preclinical lots and interim phase 1 data in relapsed/refractory myeloma showed 82% response with enhanced lymphodepletion. After electroporation, cells were pooled and cultured overnight in a G-Rex® vessel.

What this paper found

P-BCMA-ALLO1, an allogeneic anti-BCMA CAR-T product enriched in stem cell memory T cells, produced responses in heavily pretreated relapsed/refractory multiple myeloma when given after enhanced lymphodepletion. Across 27 research lots, the share of CD8+ Tscm cells correlated with tumor control in RPMI-8226 xenograft mice. In the phase I trial (NCT04960579), efficacy analysis covered 19 patients dosed at 2 × 10^6 cells/kg: response rates were 0% with cyclophosphamide 300 mg/m², 80% with 500 mg/m² and 83.3% with 1,000 mg/m². No patient needed bridging therapy, no dose-limiting toxicity or GvHD occurred, and no CRS exceeded grade 2. CAR-T cells expanded and shifted from Tscm toward effector phenotype, and were also found in bone marrow. Data cutoff was October 23, 2023.

Note: Interim phase I data come from a non-planned post-hoc analysis of 34 participants.

Notably, none of the patients required BT, resulting in a 100% dosing rate for the ITT population. — Hubert Tseng, Bhagirathbhai Dholaria, Stacey A. Cranert, Maximilian Richter, Karl S. Marquez, Benjamin S. Cho, Andrew Bacong, Katherine McArthur, Jeff D. Eskew, Joanne McCaigue, Sabrina Haag, Aly Krasny, Brian Solimine, Michael J. Coffey, Aimee Loyola, Jasmine Kwong, Leyla Shune, Andrew Kin, Caitlin L. Costello, Mehmet H. Kocoglu, Aravind Ramakrishnan, Hamid Namini, Christopher E. Martin, Rajesh Belani, Julia Coronella, Devon J. Shedlock, Nature Communications

Study details

Authors
Hubert Tseng, Bhagirathbhai Dholaria, Stacey A. Cranert, Maximilian Richter, Karl S. Marquez, Benjamin S. Cho, Andrew Bacong, Katherine McArthur, Jeff D. Eskew, Joanne McCaigue, Sabrina Haag, Aly Krasny, Brian Solimine, Michael J. Coffey, Aimee Loyola, Jasmine Kwong, Leyla Shune, Andrew Kin, Caitlin L. Costello, Mehmet H. Kocoglu, Aravind Ramakrishnan, Hamid Namini, Christopher E. Martin, Rajesh Belani, Julia Coronella, Devon J. Shedlock
Journal
Nature Communications
Year
2025
PMID / PMC
PMID: 41285709 · PMC
Cell type(s)
CAR T Cells
Application area
Hematologic malignancy
Study phase
Phase I

How G-Rex® was used

Preclinical research lots of P-BCMA-ALLO1 were made in a G-Rex® culture vessel from Wilson Wolf. After electroporation of CD4+ and CD8+ T cells with sPB and Cas-CLOVER mRNAs, gRNAs and a CAR transposon plasmid, cells from multiple reactions were pooled and cultured overnight in supplemented medium in the G-Rex® vessel. The next day, methotrexate was added to activate the cells and deplete CAR-negative cells, and the culture was maintained with regular fresh medium replenishment. Small-scale research lots were produced over 14 days, with an average expansion of 6.93-fold across 27 preclinical lots, before depletion of residual TCR-positive cells and cryopreservation.

Explore related

Full citation

Tseng H, Dholaria B, Cranert SA, et al. TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial. Nat Commun. 2025;16(1):10050.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →